Understanding the dynamics: Pathways involved in the pathogenesis of rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 51, Issue SUPPL.5, 2012, Pages

  Choy, Ernest ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

B cell; Cytokine; Interleukin 1; Interleukin 17; Interleukin 6; Pathogenesis; Pathophysiology; Rheumatoid arthritis; T cell; Tumour necrosis factor

Indexed keywords

ABATACEPT; ACUTE PHASE PROTEIN; ADALIMUMAB; AUTOANTIBODY; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 6; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE PHASE RESPONSE; ANEMIA; ANGIOGENESIS; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; BONE DESTRUCTION; CARDIOVASCULAR DISEASE; CARTILAGE CELL; CARTILAGE DEGENERATION; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEPRESSION; DRUG MECHANISM; EFFECTOR CELL; FATIGUE; FIBROBLAST; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOPATHOGENESIS; LYMPHOCYTE DIFFERENTIATION; MONONUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; PANNUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL;

ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CYTOKINES; HUMANS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84863861008     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes113     Document Type: Article

References (83)

1. Cimmino MA, Parisi M, Moggiana G, Mela GS, Accardo S. Prevalence of rheumatoid arthritis in Italy: the Chiavari Study. Ann Rheum Dis 1998;57:315-8.
2. Carbonell J, Cobo T, Balsa A, Descalzo MA, Carmona L. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology 2008; 47:1088-92.
3. Symmons D, Turner G, Webb R et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002;41:793-800.
4. Riise T, Jacobsen BK, Gran JT. Incidence and prevalence of rheumatoid arthritis in the county of Troms, northern Norway. J Rheumatol 2000;27:1386-9.
5. Simonsson M, Bergman S, Jacobsson LT, Petersson IF, Svensson B. The prevalence of rheumatoid arthritis in Sweden. Scand J Rheumatol 1999;28:340-3.
6. Saraux A, Guedes C, Allain J et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. J Rheumatol 1999;26:2622-7.
7. Boyer GS, Benevolenskaya LI, Templin DW et al. Prevalence of rheumatoid arthritis in circumpolar native populations. J Rheumatol 1998;25:23-9.
8. Jacobsson LT, Hanson RL, Knowler WC et al. Decreasing incidence and prevalence of rheumatoid arthritis in Pima Indians over a twenty-five-year period. Arthritis Rheum 1994;37:1158-65.
9. Plenge RM. Rheumatoid arthritis genetics: 2009 update. Curr Rheumatol Rep 2009;11:351-6.
10. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
11. Gonzalez A, Maradit KH, Crowson CS et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56:3583-7.
12. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88.
13. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74.
14. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801-6.
15. Klareskog L, Padyukov L, Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 2007;19:49-54.
16. Getts MT, Miller SD. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: triggering of autoimmune diseases by infections. Clin Exp Immunol 2010;160:15-21.
17. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008;24:469-80.
18. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 2010; 49:15-24.
19. Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 2005;23:S43-52.
20. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42.
21. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
22. Panichi V, Migliori M, De Pietro S et al. The link of biocompatibility to cytokine production. Kidney Int 2000; 58:96-103.
23. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108: 2957-63.
24. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351-62.
25. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther 2007;9:203.
26. Kudo O, Sabokbar A, Pocock A et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1-7.
27. Lally F, Smith E, Filer A et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum 2005;52:3460-9.
28. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002;4:S81-90.
29. Nakahara H, Song J, Sugimoto M et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003;48:1521-9.
30. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271-6.
31. de Benedetti F, Rucci N, Del Fattore A et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006;54: 3551-63.
32. Poli V, Balena R, Fattori E et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994;13:1189-96.
33. Nalbandian A, Crispin JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009;157:209-15.
34. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8.
35. Koenders MI, Lubberts E, Oppers-Walgreen B et al. Induction of cartilage damage by overexpression of T cell interleukin-17A in experimental arthritis in mice deficient in interleukin-1. Arthritis Rheum 2005;52:975-83.
36. Shahrara S, Huang Q, Mandelin AM, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther 2008;10: R93.
37. Yue C, You X, Zhao L et al. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 2010;30:1553-7.
38. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-7.
39. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467-76.
40. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334(Pt 2): 297-314.
41. Rabe B, Chalaris A, May U et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008;111:1021-8.
42. McLoughlin RM, Jenkins BJ, Grail D et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci USA 2005;102:9589-94.
43. Nowell MA, Richards PJ, Fielding CA et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2006;54: 2084-95.
44. Yang L, Anderson DE, Baecher-Allan C et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008;454:350-2.
45. Volpe E, Servant N, Zollinger R et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008;9:650-7.
46. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008;9:641-9.
47. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
48. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003;62:ii60-7.
49. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102: 783-8.
50. Combe B, Dougados M, Goupille P et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001; 44:1736-43.
51. Nikolaisen C, Figenschau Y, Nossent JC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol 2008;35: 380-6.
52. Demirag MD, Haznedaroglu S, Sancak B et al. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern Med 2009;48: 421-6.
53. del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
54. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460-9.
55. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
56. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3104-12.
57. Hewlett S, Cockshott Z, Byron M et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005;53:697-702.
58. Kojima M, Kojima T, Suzuki S et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:1018-24.
59. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.
60. Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 1995;22: 639-43.
61. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA. Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum 2004;51:578-85.
62. Chrousos GP. Regulation and dysregulation of the hypothalamic-pituitary-adrenal axis. The corticotropin-releasing hormone perspective. Endocrinol Metab Clin North Am 1992;21:833-58.
63. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992;267:1244-52.
64. Eijsbouts AM, van den Hoogen FH, Laan RF et al. Hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23: 658-64.
65. Harle P, Straub RH, Wiest R et al. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. Ann Rheum Dis 2006;65:51-6.
66. Harbuz MS, Korendowych E, Jessop DS et al. Hypothalamo-pituitary-adrenal axis dysregulation in patients with rheumatoid arthritis after the dexamethasone/ corticotrophin releasing factor test. J Endocrinol 2003;178:55-60.
67. Remicade® (infliximab) for IV injection [prescribing information]. Malvern, PA, USA: Centocor Ortho Biotech, Inc., 2009.
68. Remicade 100 mg powder for concentrate for solution for infusion [summary of product characteristics]. Leiden, The Netherlands: Centocor B.V., 2009.
69. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-12.
70. Enbrel 25 mg powder and solvent for solution for injection [summary of product characteristics]. Berkshire, UK: Wyeth Europa Ltd, 2010.
71. Enbrel- (etanercept) for subcutaneous injection [prescribing information]. Thousand Oaks, CA, USA: Amgen Inc. and Wyeth Pharmaceuticals, 2009.
72. Humira 40 mg solution for injection [summary of product characteristics]. Berkshire, UK: Abbott Laboratories Ltd, 2010.
73. Humira (adalimumab) injection, solution [prescribing information]. North Chicago, IL, USA: Abbott Laboratories, 2009.
74. Cimzia- 200 mg solution for injection [summary of prescribing information]. Brussels, Belgium: UCB, Inc., 2009.
75. Cimzia- (certolizumab pegol) [prescribing information]. Smyrna, GA, USA: UCB, Inc., 2009.
76. Simponi 50 mg solution for injection in pre-filled pen [summary of product characteristics]. Leiden, The Netherlands: Centocor B.V., 2009.
77. Kineret 100 mg solution for injection [summary of product characteristics]. Stockholm, Sweden: Biovitrum AB, 2009.
78. RoActemra 20 mg/ml concentrate for solution for infusion [summary of product characteristics]. Welwyn Garden City, UK: Roche Registration Ltd, 2009.
79. MabThera 100 mg (10mg/ml) concentrate for solution for infusion [summary of product characteristics]. Welwyn Garden City, UK: Roche Registration Ltd, 2008.
80. Orencia® 250 mg powder for concentrate for solution for infusion [summary of product characteristics]. Uxbridge, UK: Bristol-Meyers Squibb Pharma EEIG, 2009.
81. Scheinecker C, Redlich K, Smolen JS. Cytokines as therapeutic targets: advances and limitations. Immunity 2008;28:440-4.
82. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology 2012; 51(Suppl 5):38-47.
83. Feely MG, Erickson A, O'Dell JR. Therapeutic options for rheumatoid arthritis. Expert Opin Pharmacother 2009;10: 2095-106.